other material
confidence high
sentiment positive
materiality 0.60
Vericel launches NexoBrid in U.S. for severe thermal burns; $300M addressable market
Vericel Corp
- Full commercial launch of NexoBrid for eschar removal in adults with deep partial/full-thickness thermal burns.
- Selective enzymatic debridement preserves viable tissue vs. surgical excision.
- Addressable U.S. market of ~30,000 patients/year, equating to $300 million.
- Product can be applied in up to two 4-hour sessions covering up to 20% total body surface area.
- Launch expands Vericel's Burn Care franchise and diversifies revenue stream.